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Loperamide is a synthetic μ-opioid agonist; it is an
effective antidiarrheal agent as it inhibits peristalsis and
increases rectal tone owing to agonism at intestinal opioid
receptors. It was previously thought to have a low potential
for abuse owing to its low bioavailability and poor
penetration of the central nervous system through the
blood–brain barrier.1,2 There is recent literature that sup-
ports loperamide being taken in very large dosages to
achieve alleviation of opioid withdrawal symptoms and
also to obtain euphoric effects.3 Massively high sustained
doses of loperamide appear to have the potential to exert
cardiac effects. In very high and chronic doses, loperamide
use is implicated with signiﬁcant cardiac conduction
abnormalities and life-threatening dysrhythmias.4,5
We detail a case of a young woman who self-treated her
“opiate withdrawal” with chronic massive intake of loper-
amide and cimetidine abuse and presented with profound
electrical conduction disturbances, which resolved after drug
cessation.
Case report
A 28-year-old woman was transferred to our hospital for
ventricular arrhythmias after presenting to an outside hospi-
tal with several episodes of syncope over the past 2 weeks.
Her syncopal events occurred mostly at rest and were
preceded by palpitations and rapid darkening of her vision.
At the outside hospital, her initial electrocardiogram (ECG)
showed sinus rhythm with QRS widening and a prolonged
corrected QT interval (QTc) of 795 ms, per report. There she
was admitted for further evaluation and she had severalKEYWORDS Loperamide; Cimetidine; Ventricular tachycardia; Isoproterenol;
Opiate withdrawal; External pacemaker
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cope, which all resolved spontaneously or after brief
cardiopulmonary resuscitation.
A thorough diagnostic evaluation ensued and was largely
normal. Echocardiogram showed normal left ventricular size
and systolic function with ejection fraction of 55%–65%.
Computed tomography of the chest was unremarkable.
Cardiac magnetic resonance imaging (MRI) was normal,
without structural abnormalities. MRI of the brain was
normal. QRS widening, QTc prolongation, and ventricular
arrhythmias persisted throughout her initial course.
A lidocaine bolus and amiodarone infusion were used brieﬂy
but were discontinued before her eventual transfer to our
tertiary care hospital on hospital day 5.
Vital signs upon arrival after transfer were as follows:
temperature 98.11F, heart rate 77 beats per minute (bpm),
blood pressure 136/69 mm Hg, respiratory rate 16 breaths
per minute, and oxygen saturation 100% on room air.
Physical examination was unremarkable except for II/VI
systolic heart murmur. ECG showed sinus bradycardia, rate
56 bpm, with ﬁrst-degree heart block, right axis deviation,
and QRS interval of 192 ms and QTc of 642 ms with T wave
inversions in lead V2-V4 and T wave ﬂattening in the lateral
and inferior leads (Figure 1). Complete blood count was
normal other than a white blood cell count of 12.8  103;
complete metabolic panel was remarkable only for potas-
sium of 3.2 mg/dL. Magnesium and phosphorus were within
normal limits.
Shortly after arrival to our hospital she had 2 witnessed
syncopal episodes associated with brief myoclonic jerking
and ventricular dysrhythmias. The ﬁrst occurred during 15
seconds of a sustained wide complex rhythm (Figure 2). The
second was 58 seconds of a monomorphic wide complex
ventricular rhythm with the following rhythm strip and ECG
(Figure 3). Each dysrhythmia-associated syncopal episode
self-resolved with spontaneous conversion back to sinus
rhythm prior to intervention. Because of bradycardia-
induced torsade de pointes (Figure 4), an isoproterenolan open access article under the CC BY-NC-ND license
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KEY TEACHING POINTS
 Loperamide, when taken chronically in large doses,
can cause signiﬁcant conduction abnormalities and
ventricular arrhythmias that are reversible upon
discontinuation of the drug.
 Isoproterenol may serve as a useful adjunct for
preventing loperamide-induced ventricular
arrhythmias, particularly torsades de pointes.
 Familiarity with and recognition of the dangers of
loperamide abuse may preclude unnecessary
diagnostics and invasive procedures.
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rate of 90 bpm, and a transvenous pacemaker was also
inserted in the event she should require overdrive pacing.
The patient denied any history of prior cardiac disease or
syncope. She denied any current illicit drug or alcohol abuse.
There was no family history of sudden or unexplained death.
She reported a remote history of hydromorphone abuse. She
had been taking her current home medications, including
loperamide, cimetidine, and gabapentin, since discontinuing
hydromorphone, after reading on the Internet that they could
ease opioid withdrawal symptoms. It was then that she divulged
her chronic, massive intake of loperamide and cimetidine when
further questioned. In fact, for the past several months on a daily
basis she had been routinely ingesting 400–600 mg of
loperamide (in the form of 2 mg tablets) and 2000 mg of
cimetidine (in form of 200 mg tablets). Moreover, she had stillFigure 1 Patient’s initial electrocardiogram after transfer, hbeen ingesting approximately 100 tablets of loperamide and 10
tablets of cimetidine daily from her private stock of medication
during her ﬁrst hospitalization, unbeknownst to the medical
staff. Once this intake was recognized at our facility, she was
educated about the dangers of this practice and the patient
subsequently discontinued loperamide and cimetidine intake.
The drug-induced cardiac effects persisted for several
days but slowly improved. Initial trials to wean isoproterenol
were unsuccessful, resulting in slowing of the heart rate,
widening of the QTc, and ventricular ectopy. Isoproterenol
was continued for 5 days to maintain an increased heart rate
and effectively prevent signiﬁcant ventricular ectopy. The
QTc, measured while isoproterenol infusion was held,
slowly narrowed over the course of her 11-day stay in our
intensive care unit. The narrowest QTc measured was 492
ms while at rest. Echocardiography was repeated and was
essentially normal. She was predominantly bradycardic after
discontinuation of the isoproterenol, with a heart rate (bpm)
ranging from the 40s to the 70s. Genetic testing for long QT
syndrome was to be considered at a later time, but this
condition was thought less likely given her steady improve-
ment. She was started on nadolol 40 mg per os daily, which
was tolerated well. Final ECG prior to discharge showed
normal QRS interval and QTc 516 ms (Figure 5). She was
discharged home on hospital day 16 and was doing well
upon phone contact several days later.
Serum concentration of loperamide, drawn shortly after
her transfer to our facility, was 83.2 ng/mL (therapeutic
range, 0.24–3.1 ng/mL) and cimetidine was 6 μg /mL
(therapeutic range, 0.5–1.5 μg/mL). Ultraperformance liquid
chromatography–time-of-ﬂight mass spectrometry of the
urine only showed the presence of cimetidine, morphine,ospital day 5, PR 210 ms, QRS 192 ms, QTc 642 ms.
Figure 2 Wide complex arrhythmia during initial syncopal episode.
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presence of morphine was consistent with the morphine she
was administered during her ﬁrst hospital stay. Methadone,
amphetamines, and cocaine were not detected.Discussion
Marraffa et al4 recently reported a small case series of 5
patients, detailing high-dose chronic loperamide abuse with
ECG changes, namely QRS and QTc prolongation, and aFigure 3 Wide complex tachycardiavariety of ventricular dysrhythmogenic events. Similar to our
case, the 5 patients within this case series all had QRS
widening and QTc prolongation, which improved or nor-
malized with discontinuation of loperamide. T wave inver-
sions across the precordial leads was another commonality
seen in several of these cases. The mechanism of the cardiac
conduction defects is not well understood, but there are
simulated model data that suggest loperamide is a human
ether-a-go-go gene (HERG) coded rectiﬁer potassium ion
current channel inhibitor.6 Methadone, another opioid, isduring second syncopal episode.
Figure 4 Bradycardia-induced torsades de pointes.
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inhibition of the rapidly activating component of the delayed
potassium ion current.7 The widened QRS interval would
suggest some element of sodium channel blockade, but there
is little known about the effects of loperamide on sodium
channels. In our patient, we were not able to exclude an
underlying channelopathy, but the discontinuation of loper-
amide and supportive care led to gradual but dramatic
improvement in QRS and QT intervals and abatement of
ventricular arrhythmias.
Loperamide is primarily metabolized by cytochrome
p450 (CYP) 3A4 and CYP2C8 and it is also a
p-glycoprotein efﬂux transporter substrate.8,9 The therapeu-
tic pharmacokinetic half-life of loperamide is approximately
9–14 hours.10 Extremely high doses may saturate the
metabolic pathway and the excretory efﬂux transport,
allowing it to exert central nervous system and other
physiological effects. The prolonged effects of loperamide
as demonstrated in this case are not unexpected in terms of
pharmacokinetic principles. The half-life can be quite
prolonged in supratherapeutic dosages.5,11 Eggleston et al5
reported a half-life of 34.8 hours in a case of QRS and QTc
prolongation with ventricular dysrhythmia. The decreased
intestinal motility seen with loperamide may also contribute
to delayed and ongoing absorption. In addition to increasedFigure 5 Final electrocardiogram before dischargbody burden of absorbed drug from chronic abuse, the
patient theoretically may have had ongoing absorption from
gastrointestinal contents from recent ingestions, given the
delayed gastrointestinal motility expected with chronic
loperamide use.
The concurrent use of cimetidine is a unique aspect to this
case not previously reported. Cimetidine, a histamine type 2
receptor antagonist, is also a well-known CYP3A inhibitor.12
It is likely that the intent of simultaneous use of cimetidine,
another affordable over-the-counter product, is to take
advantage of CYP inhibition and slow the metabolism of
loperamide, lending to higher concentrations and desired
effect. Cimetidine is a p-glycoprotein substrate but not a
known inhibitor to cause increased loperamide serum con-
centrations by blockade of efﬂux transport.8 It is not certain,
but it is unlikely that cimetidine was directly responsible for
the cardiac effects seen in this case. It has not been a noted
co-ingestant in other reported chronic loperamide overdose
cases with similar features and is not known to have such
effects in isolated overdose. There are some sparse scientiﬁc
reports detailing sinus arrest and hypotension associated with
intravenous cimetidine use, especially with rapid bolus, but it
has not been described with oral administration.13–15
Delayed recognition of excessive loperamide intake
appears to be a common feature in our and other case reportse, hospital day 15, QRS 80 ms, QTc 516 ms.
Heart Rhythm Case Reports, Vol 2, No 3, May 2016236of loperamide-associated cardiac conduction abnormalities.4
This appears to be a product of patient discretion and lack of
physician awareness regarding the potential danger of this
over-the-counter product.
Conclusion
This case details the very serious and potentially life-
threatening cardiac dysrhythmias that are associated with
both chronic and very high doses of loperamide. Loperamide
may not be as innocuous as once thought, when purposefully
abused in chronic, high quantities. Isoproterenol infusion
was very successful in eliminating ventricular arrhythmias in
this setting. Loperamide overdose should be considered,
when case appropriate, as a potential cause in similar cases of
signiﬁcant cardiac syncope and cardiac conduction distur-
bances with prolonged QRS and QTc intervals. Given the
ubiquity of loperamide and the epidemic of opioid abuse, this
may represent a growing problem. The number of new cases
warrants further investigation and physician provider
awareness.
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